463363-02-2

Upstream product

• 64019-78-9 4,7-dimethoxy-phthalide 
• 58662-54-7 5-benzyloxy-2-nitrobenzaldehyde 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 887645-21-8 4,7-dimethoxy-2-(2-nitro-5-benzyloxyphenyl)indane-1,3-dione 
• 100-44-7 benzyl chloride 
• 89449-77-4 3-Bromo-4,7-dimethoxyphthalide 

Downstream Products

• 463363-06-6 1-hydroxy-4-methoxy-8-benzyloxy-5H-indeno[1,2-b]indol-10-one 

Relevant academic research and scientific papers

New ligands at the?melatonin binding site MT3

The third melatonin binding site, MT3 is a non-classical one since it is not a seven transmembrane domains receptor, but an enzyme, quinone reductase 2. A major concern for the study of the physiological role of this site is the lack of specific ligands, permitting to more accurately dissect the pathways linked to the activation of MT3. Indeed, in the course of finding new ligands, we identified a new series of compounds with affinity to the binding site in the nM range, particularly 2,3-dimethoxy 7-hydroxy 10-methyl 5H 10H indeno(1,2-b)indol-10-one (DMHMIO), with a Ki of 190 pM. Based on slightly different and novel synthons compared to most of the compounds used in melatonin pharmacology studies, these compounds offer new perspective for the description of the melatonin pathways, so much more by not having any affinity towards the MT1 and MT2 'classical' melatonin receptors.

Indenoindolone compounds

Compound of formula (I): wherein: R represents hydrogen or a group selected from alkenyl and optionally substituted alkyl, each of R1 to R8, which may be identical or different, represents hydrogen or a group selected from alkyl, alkenyl, hydroxy, alkoxy, alkenyloxy, arylalkyl, arylalkoxy, carboxy, acyloxy and arylcarbonyloxy, or one of R1 to R8 forms with an adjacent one R1 to R8 an alkylenedioxy group, its optical isomers when they exist, and addition salts thereof with a pharmaceutically acceptable acid or base, with the proviso that: when R does not represent hydrogen, then at least one of R1 to R8 represents hydroxy or acyloxy, and the compounds of formula (I) are other than indeno[1,2-b]indol-10(5H)-one. Medicinal products containing the same which are useful for treatment of disorders of the melatoninergic system.